Hemab Therapeutics (NASDAQ:COAG) Shares Down 7.2% – Time to Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares were down 7.2% during trading on Tuesday . The stock traded as low as $25.01 and last traded at $25.19. Approximately 54,928 shares traded hands during trading, a decline of 79% from the average daily volume of 257,588 shares. The stock had previously closed at $27.15.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Price Performance

Hemab Therapeutics (NASDAQ:COAG) last released its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 2,902,872 shares of company stock worth $53,769,784 in the last quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.